EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Racial and socioeconomic disparities in survival among patients with metastatic non–small cell lung cancer

Dipesh Uprety iD, Randell Seaton, Tarik Hadid, Hirva Mamdani, Ammar Sukari, Julie J Ruterbusch, Ann G Schwartz

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Dipesh Uprety und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Socioeconomic Factors, SEER Program. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Karmanos Cancer Institute Core and Service Incentive Program, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors have profoundly impacted survival among patients with metastatic non–small cell lung cancer. However, population-based studies evaluating this impact on survival by race and socioeconomic factors are lacking.

Methods

We used the Surveillance, Epidemiology, and End Results Program–Medicare database to identify patients with metastatic non–small cell lung cancer diagnosed between 2015 and 2019. The primary study outcomes were the receipt of an immune checkpoint inhibitor and overall survival. χ2 tests and logistic regression were used to identify demographic factors associated with receipt of immune checkpoint inhibitors. The Kaplan–Meier method was used to calculate 2-year overall survival rates, and log-rank tests were used to compare survival by race and ethnicity.

Results

Of 17 134 patients, approximately 39% received an immune checkpoint inhibitor. Those diagnosed with cancer recently (in 2019); who are relatively younger (aged younger than 85 years); non-Hispanic White, non-Hispanic Asian, or Hispanic; living in high socioeconomic status or metropolitan areas; not Medicaid eligible; and with adenocarcinoma histology were more likely to receive immune checkpoint inhibitors. The 2-year overall survival rate from diagnosis was 21% for the overall population. The 2-year overall survival rate from immune checkpoint inhibitor initiation was 30%, among those who received at least 1 cycle and 11% among those who did not receive immune checkpoint inhibitors. The 2-year overall survival rates were higher among non-Hispanic White (22%) and non-Hispanic Asian (23%) patients compared with non-Hispanic Black (15%) and Hispanic (17%) patients. There was no statistically significant racial differences in survival for those who received immune checkpoint inhibitors.

Conclusion

Immune checkpoint inhibitor utilization rates and the resulting outcomes were inferior for certain vulnerable groups, mandating the need for strategies to improve access to care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSocioeconomic FactorsSEER ProgramHealthcare DisparitiesHumansAgedFemaleMaleAged, 80 and overUnited StatesImmune Checkpoint InhibitorsMedicareSurvival RateRacial GroupsSocioeconomic Disparities in Health

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Population Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

ORCID-Profile: Dipesh Uprety

Förderung

  • NCI NIH HHS
  • Karmanos Cancer Institute Core and Service Incentive Program
  • AstraZeneca
  • National Cancer Institute Center
  • Epidemiology Research Core
  • California Department of Public Health
  • Karmanos Cancer Institute at Wayne State University

Zitieren

APA

Uprety, D., Seaton, R., Hadid, T., Mamdani, H., Sukari, A., Ruterbusch, J. J., & Schwartz, A. G. (2024). Racial and socioeconomic disparities in survival among patients with metastatic non–small cell lung cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae118

Vancouver

Uprety D, Seaton R, Hadid T, Mamdani H, Sukari A, Ruterbusch JJ, et al. Racial and socioeconomic disparities in survival among patients with metastatic non–small cell lung cancer. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae118

BibTeX
@article{Uprety2024,
  author = {Uprety, Dipesh and Seaton, Randell and Hadid, Tarik and Mamdani, Hirva and Sukari, Ammar and Ruterbusch, Julie J and Schwartz, Ann G},
  title = {Racial and socioeconomic disparities in survival among patients with metastatic non–small cell lung cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae118}
}
Kostenlos starten →